Palovarotene MOA

Share this article with:

Fibrodysplasia ossificans progressiva, or FOP, is an extremely rare and debilitating disorder, in which bone tissue gradually replaces soft tissue throughout the body, extending the skeleton and “freezing” patients into position. FOP is an autosomal dominant disorder, and is believed to be caused by a mutation in the ACVR1 gene, which results in constitutively active BMP signaling. Clementia Pharmaceuticals is investigating Palovarotene as a RAR-gamma agonist capable of inhibiting BMP signaling, which may prevent heterotopic ossification and slow the progression of this devastating disease.

Share It:
Contact XVIVO


Palovarotene MOA

XVIVO is top notch! I work with a lot of vendors on behalf of my clients and XVIVO exceeding my expectations every time. Not only was the work outstanding, the service was as well. Even when things got crazy, and they did several times, XVIVO delivered with a positive, can do it attitude – making my life and direct contact with the client much easier.

Account Director, Palio Communications